MYRIAD GENETICS (MYGN) Company Report

Myriad Genetics reported preliminary Q4 2025 revenue between $207 million and $209 million and full-year 2025 revenue between $822 million and $824 million, with overall volume growth of 1% for the year.
For 2026, the company provided guidance of $860 million to $880 million in revenue, representing 6% growth at the midpoint, with gross margins of 68%-69% and adjusted EBITDA between $37 million and $49 million.
The company plans to achieve high-single-digit to low-double-digit revenue growth over the next five years, starting in 2025, by focusing on the cancer care continuum and expanding its product portfolio.
Key product developments for 2026 include the launch of an AI-enabled Prolaris test in the first half, initial testing and MolDX submissions for the Precise MRD test, and the full commercial launch of FirstGene in the second half.
Myriad intends to invest over $35 million over the next few years to strengthen commercial capabilities, particularly in cancer care, with these expenses already factored into the 2026 guidance.

6 days ago

Transcript

Myriad Genetics Provides 2025 Preliminary Results and 2026 Guidance, Outlines Strategic Focus

MYGN

Guidance Update

Product Launch

New Projects/Investments

Myriad Genetics reported preliminary Q4 2025 revenue between $207 million and $209 million and full-year 2025 revenue between $822 million and $824 million.
For full-year 2026, the company projects revenue between $860 million and $880 million, gross margin of 68%-69%, and adjusted EBITDA between $37 million and $49 million.
Myriad Genetics is undergoing a strategic shift, focusing on the cancer care continuum and expanding its product portfolio, including new AI-enabled tests and significant investment in Minimal Residual Disease (MRD).
The company anticipates achieving high-single-digit to low-double-digit revenue growth over the next five years, starting in 2025, driven by new product launches and strategic partnerships.

6 days ago

Transcript

Myriad Genetics Reports Preliminary 2025 Results and Issues 2026 Guidance

MYGN

Guidance Update

Product Launch

New Projects/Investments

Myriad Genetics reported preliminary Q4 2025 revenue of $207-$209 million and FY 2025 revenue of $822-$824 million.
The company provided 2026 financial guidance, projecting total revenue of $860-$880 million, an adjusted gross margin of 68%-69%, and adjusted EBITDA of $37-$49 million. The mid-point of 2026 revenue guidance reflects an approximate 6% increase over the preliminary 2025 revenue mid-point.
Myriad is strategically focusing on the Cancer Care Continuum and plans to launch new products in H1 2026, including an AI-enhanced Prolaris test for prostate cancer and initiating clinical testing for Precise MRD for breast cancer.
In 2025, the company served 55K+ healthcare providers and reported 1.5M+ patient tests.
Myriad plans to invest over $35 million in its commercial organization to drive strategic growth.

6 days ago

Presentation

Myriad Genetics Announces Preliminary Q4 and Full Year 2025 Results and Full Year 2026 Guidance

MYGN

Earnings

Guidance Update

Revenue Acceleration/Inflection

Myriad Genetics announced preliminary total revenues for Q4 2025 to be between $207 million and $209 million, and for full year 2025 between $822 million and $824 million.
The company introduced full year 2026 financial guidance, projecting revenue between $860 million and $880 million, which reflects an approximate 6% increase compared to the midpoint of the preliminary 2025 revenue range.
For full year 2026, Adjusted Gross Margin is guided to be 68% - 69%, and Adjusted EBITDA is expected to be between $37 million and $49 million, with the midpoint representing an approximate 43% growth over the midpoint of the previous full year 2025 guidance range.
Total test volumes for full year 2025 are expected to be approximately 1.5 million, a 1% year-over-year increase, with 7% growth in hereditary cancer testing and 6% growth in mental health testing, offset by a 4% decrease in prenatal health testing volume.

Jan 12, 2026, 1:31 PM

8-K

Myriad Genetics Announces Preliminary Q4 and Full Year 2025 Results and 2026 Guidance

MYGN

Earnings

Guidance Update

Revenue Acceleration/Inflection

Myriad Genetics expects preliminary unaudited total revenues for the fourth quarter of 2025 to be between $207 million and $209 million, and for the full year 2025 between $822 million and $824 million.
The company introduced full year 2026 financial guidance, projecting revenue between $860 million and $880 million, Adjusted Gross Margin between 68% and 69%, and Adjusted EBITDA between $37 million and $49 million.
The mid-point of the 2026 revenue guidance reflects an increase of approximately 6% compared to the mid-point of the preliminary 2025 revenue range.
These preliminary 2025 results are unaudited and subject to change, with actual financial results for the fourth quarter and full year 2025 expected to be released in February 2026.

Jan 12, 2026, 1:30 PM

Press Release

Myriad Genetics Updates Strategy to Focus on Cancer Care Continuum and Prepares for MRD Launch

MYGN

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Myriad Genetics has updated its strategy to prioritize the cancer care continuum for accelerated growth, while other segments like prenatal and mental health will aim for at or above-market growth.
The company is preparing to launch Precise MRD in the first half of next year (2026), a differentiated minimal residual disease assay, which is expected to be a significant growth driver.
The GeneSight test is projected to generate over $150 million in revenue this year, demonstrating mid-single to low double-digit growth despite UnitedHealthcare's decision not to change its policy for 2026.
Myriad's hereditary cancer business is showing a return to growth, with 16% volume growth in the affected market and 11% volume growth in the unaffected market in the last quarter, driven by workflow improvements.
The launch of MRD is expected to impact gross margins in 2026 and 2027, though the company anticipates cost reductions through scale.

Dec 2, 2025, 5:00 PM

Transcript

Myriad Genetics Outlines Strategic Focus on Cancer Care Continuum and Upcoming Product Launches

MYGN

Product Launch

Revenue Acceleration/Inflection

New Projects/Investments

Myriad Genetics is updating its strategy to focus on the cancer care continuum for accelerated, profitable growth, while other segments like mental health and prenatal health will aim for at or above-market growth.
The company reported a return to mid-single-digit growth for its GeneSight test in Q2 and Q3, projecting over $150 million in revenue this year, and has secured over 10 new payers for the test.
Myriad's hereditary cancer business demonstrated strong performance last quarter, with 16% volume growth in the affected market and 11% volume growth in the unaffected market, which represents a $5 billion opportunity.
Upcoming product launches include FirstGene, a combined prenatal and hereditary cancer screening product, and Precise MRD, a differentiated Minimal Residual Disease assay, both expected to launch commercially next year. The new molecular and AI-combined Prolaris prostate cancer test is also set for a 2026 launch.

Dec 2, 2025, 5:00 PM

Transcript

Myriad Genetics Updates Strategy and Product Pipeline

MYGN

Product Launch

Revenue Acceleration/Inflection

New Projects/Investments

Myriad Genetics has updated its strategy to focus on the cancer care continuum for accelerated growth, while other segments like prenatal and mental health will aim for at or above-market growth.
The company is experiencing a return to growth in key areas, with GeneSight showing mid-single to low double-digit growth and the unaffected hereditary cancer market growing 11% in volume last quarter after a Q1 decline.
New product launches and updates include an enhanced MyRisk product with 63 genes, the Prequel NIPS test (performable at eight weeks gestational age), and the upcoming Precise MRD assay in the first half of 2026.
Despite challenges like the UnitedHealth policy decision for GeneSight (which will remain unchanged for 2026) and NCCN guideline confusion for Prolaris, Myriad has added over 10 additional payers for GeneSight and is conducting studies to address guideline inclusion for Prolaris.
Myriad anticipates high single-digit to low double-digit sustained, profitable growth for the company, with the launch of MRD expected to impact gross margins in 2026 and 2027.

Dec 2, 2025, 5:00 PM

Transcript

Myriad Genetics Outlines Strategic Transformation and Product Pipeline

MYGN

Revenue Acceleration/Inflection

New Projects/Investments

Product Launch

Myriad Genetics is undergoing a transformation, targeting high single-digit to low double-digit revenue growth over the next three to five years by focusing on the cancer care continuum. The company is committed to growing revenue faster than operating expenses and has invested $35 million in commercial capabilities.
The company plans a controlled early access launch of its Precise MRD assay in 2026, with a full commercial launch in 2027, emphasizing its ultra-ultrasensitive detection for low-shedding tumors and ongoing pharma partnerships.
Other key product developments include an updated MyRisk hereditary cancer panel , a liquid biopsy partnership with SOPHiA GENETICS and Memorial Sloan Kettering expected to ramp up in Q1 2026 , and a combined molecular and AI approach for Prolaris (prostate cancer test) starting in 2026, with a second product in 2027.
Hereditary cancer testing is expected to generate $370 million in revenue this year, accounting for 45% of sales and growing in low single digits, with significant growth opportunities in the unaffected segment.

Nov 18, 2025, 6:20 PM

Transcript

Myriad Genetics Outlines Strategic Shift and Growth Initiatives

MYGN

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Myriad Genetics is undergoing a strategic transformation, focusing on the cancer care continuum to achieve a high single-digit to low double-digit growth rate over the next three to five years.
Key product initiatives include an updated MyRisk hereditary cancer panel , a combined digital pathology and molecular test for Prolaris launching in 2026 , and the Precise MRD assay with a controlled launch in H1 2026 and full commercial launch in 2027.
The company is investing $35 million in commercial capabilities and pursuing pharma partnerships for its MRD program.
A collaboration with SOPHiA GENETICS and Memorial Sloan Kettering for liquid biopsy is expected to ramp up in Q1 2026.

Nov 18, 2025, 6:20 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for MYRIAD GENETICS.

Q3 2025

Nov 3, 2025

→

Q2 2025

Aug 5, 2025

→

Q1 2025

May 6, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Sam S. Raha say about margins?What are MYRIAD GENETICS's strategic priorities?How is MYRIAD GENETICS positioned vs competitors?How did MYRIAD GENETICS do last quarter?

MYRIAD GENETICS (MYGN)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Sam S. Raha

Ben R. Wheeler

Dale Muzzey

Jennifer Fox

Kevin R. Haas

Margaret Ancona

Mark Verratti

Shereen Solaiman

Board Members

Colleen F. Reitan

Daniel M. Skovronsky, M.D., Ph.D.

Heiner Dreismann, Ph.D.

Lee N. Newcomer, M.D.

Mark S. Davis

Paul M. Bisaro

Rashmi Kumar

S. Louise Phanstiel

Analyst Coverage

Puneet Souda

Sung Ji Nam

Tycho Peterson

Brandon Couillard

David Westenberg

Douglas Schenkel

Mason Carrico

Michael Ryskin

Tejas Savant

Andrew Cooper

Ben...

Bill Bonello

Dan Brennan

Doug Schenkel

Jason Lai

Kyle Boucher

Lu Li

Madison Pasterchick

Matt Sik

Prashant Kota

Rachel Vatnsdal Olson

Ricki Levitus

Subhalaxmi Nambi

Thomas...

William Bonello

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Q1 2025

Ask Fintool AI Agent